Citing an anticompetitive agreement that was "clearly made out," India's Competition Commission took issue with GlaxoSmithKline and Sanofi's operations in the country this week and fined the international pharma nearly $10 million.
Last summer, Chinese prosecutors sentenced Peter Humphrey--a private eye linked to GlaxoSmithKline's 2013 bribery scandal--to 2.5 years in prison. But now, after serving about two years, he's been released.
GlaxoSmithKline is already struggling with sales of aging respiratory superstar Advair, and Mylan just made its job more difficult.
India's competition watchdog said that government vaccine procurement rules favored multinational drugmakers Sanofi and GlaxoSmithKline and the companies colluded in pricing, according to the Economic Times, charges that both companies denied in response to queries from FiercePharmaAsia.
Now that it's teamed up with Novartis' consumer health unit to form an industry-leading joint venture, GlaxoSmithKline's OTC business is bigger than ever. But its payroll is about to get smaller, with 350 layoffs hitting the operation.
A move by Takeda Pharmaceutical to consolidate its Vaccine Business Unit into hubs should allow sharper focus on a complex set of vaccine programs covering norovirus, dengue and seasonal influenza in an increasingly competitive global horse race.
GlaxoSmithKline's big advertising push on over-the-counter Flonase appears to be working.
Lately, Perrigo's shown it would rather be the acquirer than the acquired--and it continued down that path Tuesday.
Some analysts may be pooh-poohing a Pfizer buyout of GlaxoSmithKline, but some investors are hip to the idea.
Some analysts may be pooh-poohing a Pfizer buyout of GlaxoSmithKline, but some investors are hip to the idea. As Bloomberg reports, options traders are paying record prices for bullish GSK options--and this after the British drugmaker lost $11 billion off its market cap in less than three months.